Regulatory approval
Published by the Health Canada.
Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK
This is written in the approval document as:
IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Gefitinib | |
| HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Gefitinib | |
| HC (1) | EGFR oncogenic variants | Non-Small Cell Lung Cancer | Gefitinib |